Red Blood Cell Transfusion
A Pocket Guide for the Clinician

Robert Weinstein, MD
University of Massachusetts Medical School
November 2016

Adapted from Red Blood Cell Transfusion: A clinical practice guideline from the AABB, Clinical Practice Guidelines from the AABB: Red blood cell transfusion thresholds and storage, and additional sources
Red Blood Cells as a Therapeutic Product

Appropriate uses of red blood cell (RBC) transfusion
- Treatment of symptomatic anemia
- Prophylaxis in life-threatening anemia
- Restoration of oxygen-carrying capacity in case of hemorrhage
- RBCs are also indicated for exchange transfusion
  - Sickle cell disease
  - Severe parasitic infection (malaria, babesiosis)
  - Severe methemoglobinemia
  - Severe hyperbilirubinemia of newborn

RBC transfusion is not routinely indicated for pharmacologically treatable anemia such as:
- Iron deficiency anemia
- Vitamin B₁₂ or folate deficiency anemia

Dosage and administration
- One unit of RBC will raise the hemoglobin of an average-size adult by ~1 g/dL (or raise HCT ~3%)
- ABO group of RBC products must be compatible with ABO group of recipient
- RBC product must be serologically compatible with the recipient (see Pretransfusion Testing). Exceptions can be made in emergencies (see Emergency Release of Blood Products).
- Rate of transfusion
  - Transfuse slowly for first 15 minutes
  - Complete transfusion within 4 hours (per FDA)

**Major Red Cell Products for Transfusion**
Most RBC products are derived by collection of 450-500 (±10%) mL of whole blood from volunteer donors and removal of the plasma by centrifugation (see Table 1). After removal of the plasma, the resulting product is red blood cells from volunteer donors and removal of the plasma by centrifugation (see Table 1).

The most commonly available US RBC product has a 42-day blood bank shelf life and HCT 55-65%.

Table 1. Special Processing of RBC for Transfusion

<table>
<thead>
<tr>
<th>Process</th>
<th>Indications</th>
<th>Technical Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukocyte Reduction</td>
<td>Decrease risk of recurrent febrile, nonhemolytic transfusion reactions</td>
<td>Most commonly achieved by filtration</td>
</tr>
<tr>
<td></td>
<td>Decrease risk of cytomegalovirus (CMV) transmission (marrow transplant)</td>
<td>Usually soon after collection (prestorage)</td>
</tr>
<tr>
<td></td>
<td>Decrease risk of HLA-alloimmunization</td>
<td>May be performed at bedside</td>
</tr>
<tr>
<td></td>
<td>Does not prevent transfusion-associated graft-versus-host disease (TA-GVHD)</td>
<td></td>
</tr>
<tr>
<td>Washing (removes residual plasma)</td>
<td>Decrease risk of anaphylaxis in IgA-deficient patient with anti-IgA antibodies</td>
<td>Wash fluid is 0.9% NaCl ± dextrose</td>
</tr>
<tr>
<td></td>
<td>Decrease reactions in patients with history of recurrent, severe allergic or anaphylactoid reactions to blood product transfusion</td>
<td>Shelf life of washed RBCs 24 hours at 1-6°C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4 hours at 20-24°C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May lose 20% of red cells in washing process</td>
</tr>
</tbody>
</table>

Irradiation
- Prevention of TA-GVHD in certain circumstances
- Decrease risk of HLA-alloimmunization
- Does not prevent transfusion-associated graft-versus-host disease
- Decrease risk of cytomegalovirus (CMV) transmission (marrow transplant recipient)
- Decrease risk of nonhemolytic transfusion reactions
- Decrease risk of recurrent febrile, nonhemolytic transfusion reactions
- Decrease risk of cytomegalovirus (CMV) transmission (marrow transplant recipient)
- Decrease risk of HLA-alloimmunization
- Decrease risk of transfusion-associated graft-versus-host disease (TA-GVHD)
- Decrease risk of recurrent febrile, nonhemolytic transfusion reactions

Pretransfusion Testing
Pretransfusional blood sample from the intended recipient
- Usually EDTA tube (plasma and red cells)
- Proper labeling of the sample
  - 2 independent patient identifiers
  - Identity of the phlebotomist
  - Date and time of sample collection
  - Sample rejected without these
  - Age of the sample
    - Up to 3 days if hospital inpatient or, in past 3 months, recipient
      - Has been pregnant
      - Has been transfused
      - Has uncertain history of either
    - Longer (often 1–2 weeks, according to hospital policy) for outpatient
      - Pre-op testing if negative history within 3 months

Pretransfusion blood sample from the intended recipient
- Usually EDTA tube (plasma and red cells)
- Proper labeling of the sample
  - 2 independent patient identifiers
  - Identity of the phlebotomist
  - Date and time of sample collection
  - Sample rejected without these
  - Age of the sample
    - Up to 3 days if hospital inpatient or, in past 3 months, recipient
      - Has been pregnant
      - Has been transfused
      - Has uncertain history of either
    - Longer (often 1–2 weeks, according to hospital policy) for outpatient
      - Pre-op testing if negative history within 3 months
Purpose

- Very Low
- Moderate
- Low
- Moderate
- Guided by symptoms as needed
- Strong

**Antibody Screen**
- Detect unexpected, clinically significant (non-ABO) anti-RBC antibodies in recipient’s plasma
- Test recipient’s plasma with phenotyped “reagent” RBCs
- Time: ~50 min

**Antibody Identification**
- Identify specificity of anti-RBC antibody if antibody screen is positive
- Test recipient’s plasma with many “reagent” RBCs
- Time: Varies: Hours to days

**Immediate Spin Crossmatch** (when antibody screen is negative)
- Ensure ABO compatibility between recipient’s plasma and RBC product chosen for transfusion
- Test recipient’s plasma with sample of red cells from product chosen for transfusion
- Time: ~10 min

**Full Serological Crossmatch** (when antibody screen is positive)
- Ensure full serological compatibility between recipient’s plasma and RBC product chosen for transfusion
- Test recipient’s plasma with sample of red cells from product chosen for transfusion. Includes extra incubations (e.g. at 37°C and with Coombs reagent)
- Time: Up to an hour

**Electronic Crossmatch** (not universally available)
- Match ABO/Rh compatible RBC from inventory with patient whose ABO/Rh status has been confirmed and who has no history of, and negative testing for, RBC alloantibodies
- Validated blood bank computer system
- Time: ~10-15 min

* A is the most common subgroup of Group A

---

**Emergency Release of Blood Products**

An emergency release of blood products is warranted when the clinical setting precludes waiting for completion of pretransfusion and compatibility testing. Examples include:
- Severe, ongoing life-threatening hemorrhage
- Life-threatening anemia

What you should do:
- Notify blood bank of need for emergency release of RBCs
- Complete hospital’s “emergency release” form
- Documents your declaration of a transfusion emergency
- U.S. federal regulations require 2 specific items on the form
  - Statement of the nature of the emergency (e.g. “massive GI hemorrhage”)
  - Signature of MD or “equivalent”; (PA, NP, RN, etc. cannot sign)
- Send patient blood sample to blood bank ASAP (before emergency transfusion begins, if possible)

What you’ll get from the blood bank (depending on how much testing has already been performed):
- Uncrossmatched RBCs (ABO group-specific if determined on a current blood specimen)
- Group O RBCs if blood bank has not documented patient’s ABO group on a fresh blood sample
- Rh neg depending on availability and hospital policy, if patient’s Rh status is unknown

Blood bank will retrospectively crossmatch all emergently issued units when it receives the patient’s testing sample

Blood bank will begin issuing type specific and crossmatched products when testing is complete

**Transfusion of Incompatible RBCs**

Clinical scenario: severe warm (or cold) autoimmune hemolytic anemia
- Patient’s plasma autoantibody reacts with all of the blood bank’s reagent red cells
- Blood bank unable to determine presence or absence of underlying alloantibodies
- All RBC units are crossmatch-incompatible

Balance of risks
- Severe anemia requiring transfusion support
- Possibility of hemolytic transfusion reaction due to undiagnosed underlying alloantibodies

**Principles of approach to this situation**
- Communication between bedside clinician and transfusion service physician is essential
  - Obtain careful history of prior transfusion or pregnancy
  - If history negative, probably safe to transfuse ABO-compatible RBCs
  - If history positive or uncertain, assess risk/benefit of delaying transfusion to complete testing
- Assess how long it may take for blood bank or reference lab to complete pretransfusion testing
- Agree on best approach to choosing among incompatible RBC units (transfusion physician will advise)
- Attempt to mitigate need for immediate transfusion: bed rest, oxygen

Ultimately, do not deprive a patient with autoimmune hemolytic anemia of a needed, lifesaving transfusion
- Autoantibody will shorten survival of transfused RBCs and patient’s endogenous RBCs to a similar extent
- Most undetected alloantibodies will cause delayed hemolytic transfusion reactions
- May be misdiagnosed as worsening of autoimmune hemolysis
- Not usually life-threatening
- Bedside team must be hypervigilant for acute intravascular hemolytic reaction during transfusion (see Adverse Effects of Transfusion)

---

**Red Blood Cell Transfusion**

**Table 3. RBC Transfusion Recommendations**

<table>
<thead>
<tr>
<th>Clinical Situation</th>
<th>Potential Transfusion Threshold</th>
<th>Strength of Recommendation</th>
<th>Quality of Supporting Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult Inpatients, Hemodynamically Stable</td>
<td>Hgb** ≤ 7 gm/dL</td>
<td>Strong</td>
<td>Moderate</td>
</tr>
<tr>
<td>ICU Patients, Hemodynamically Stable (adult or pediatric)</td>
<td>Hgb ≤ 7 gm/dL</td>
<td>Strong</td>
<td>High</td>
</tr>
<tr>
<td>Postoperative Orthopedic or Cardiac Surgery Patients</td>
<td>Hgb ≤ 8 gm/dL† or for symptoms†</td>
<td>Strong</td>
<td>Moderate</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>Hgb ≤ 8 gm/dL‡ or for symptoms‡</td>
<td>Strong</td>
<td>Moderate</td>
</tr>
<tr>
<td>Acute Coronary Syndrome</td>
<td>AABB does not recommend for or against a liberal or restrictive RBC transfusion strategy</td>
<td>Uncertain</td>
<td>Very Low</td>
</tr>
<tr>
<td>All Patients</td>
<td>Guided by symptoms as well as by Hgb level</td>
<td>Weak</td>
<td>Low</td>
</tr>
</tbody>
</table>


**Hgb=Hemoglobin level
†Cannot be generalized to the preoperative setting, where expected surgical blood loss must be taken into account in transfusion decision making.
‡ Chest pain, orthostatic hypotension or tachycardia unresponsive to fluids, or congestive heart failure.
††There remains some uncertainty regarding the risk of perioperative myocardial infarction with a restrictive transfusion strategy.
Adverse Effects of Transfusion

The most clinically important adverse effects of transfusion in medical patients are infectious or immunological phenomena. The most significant infectious risks are addressed during the donor screening process, and most blood centers employ bacteriological surveillance measures on certain blood products.

Table 4. Some Infectious Risks of Blood Transfusion (all products)

<table>
<thead>
<tr>
<th>Transfusion-Transmitted Infection</th>
<th>Residual Risk Per Transfused Component</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV</td>
<td>1 in 1,476,000</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>1 in 1,149,000</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>1 in 282,000</td>
</tr>
<tr>
<td>West Nile Virus</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Cytomegalovirus</td>
<td>50-85% of donors are carriers. Leukocyte reduction is protective.</td>
</tr>
<tr>
<td>Bacterial Infection</td>
<td>1 in 2-3,000 (mostly platelets)</td>
</tr>
<tr>
<td>Parvo D5E6</td>
<td>Relatively uncommon</td>
</tr>
</tbody>
</table>

Other Important Adverse Effects of Blood Transfusion

For any of the following, except allergic (urticarial) reactions, stop transfusion and return remaining product to blood bank with transfusion reaction report:

**Acute hemolytic transfusion reaction (AHTR):** Preformed antibodies to incompatible product (1:76,000). ABO incompatibility (1:40,000). Sometimes fatal (1:1.8x10). Presents with chills, fever, hypotension, hemoglobinuria, renal failure, back pain, DIC. Keep IV open with normal saline. Keep urine output >1 mL/kg/hour. Pressors PRN. Treat DIC.

**Delayed HTR:** Anamnestic immune response to incompatible red cell antigen. May present with fever, jaundice, falling hemoglobin, newly positive antibody screen in blood bank. Occurs 1-2 weeks after transfusion. Identify offending antibody in blood bank. Transfuse PRN with compatible RBCs.

**Fibrile non-HTR:** 0.1-1.0%. Due to preformed anti-WBC antibodies in recipient. Risk minimized with leukocyte-reduced products. ≥1°C (≥2°F) rise in temperature within 2 hours of start of transfusion with no other explanation for fever. Acetaminophen premedication if reactions are recurrent.

**Allergic (urticarial) reactions:** 1-3%. Antibody to donor plasma proteins. Presents with urticaria, pruritus, flushing, mild wheezing. Pause transfusion, administer antihistamines; may resume transfusion if reaction resolves, but still report reaction to blood bank.

**Anaphylactoid/anaphylactic:** 1:20,000-50,000. Caused by antibody to donor plasma proteins (IgA, haptoglobin, C4). Hypotension, urticaria, bronchospasm, angioedema, anxiety. Rule out hemolysis. Administer epinephrine 1:1000 0.2-0.5 ml SC, antihistamines, corticosteroids.

**Transfusion-related acute lung injury (TRALI):** ~1:10,000. Preformed HLAs or neutrophil antibodies in donor product. Hypoxemia, hypotension, bilateral pulmonary edema, transient leucopenia, and fever within 6 hours of transfusion. 10-20% fatal. Supportive care. Defer implicated donors.

**Transfusion-associated graft-versus-host disease:** Rare but almost always fatal. Immunosuppressed recipient receives transfusion from HLA-similar donor (usually a family member). Pancycopenia, maculopapular rash, diarrhea, hepatitis presenting 1-4 weeks after transfusion. Prevented by irradiating blood products.

**Transfusion-associated circulatory overload (TACO):** Approximately 1% of transfusions. New onset or exacerbation of acute respiratory distress (dyspnea, orthopnea, count) 3-6 hours after transfusion. May be associated with elevated BNP, elevated central venous pressure, left heart failure, positive fluid balance, pulmonary edema on chest x-ray. Risk factors include cardiac or renal dysfunction, female gender, age >60 years, severe anemia with volume expansion, positive fluid balance, transfusion of multiple products. Mortality rate 1.4-8.3%. Management includes stopping transfusion and other fluids, sit patient up, supplemental oxygen, diuretic therapy.

Rating System and Implications of Recommendations

As indicated in this guide, evidence-based recommendations from the AABB guidelines are separately rated according to the strength of the recommendation (strong, moderate, or weak) and the quality of the supporting evidence (high, moderate, low, or very low). These ratings are intended to have the following implications (adapted from GRADE):

<table>
<thead>
<tr>
<th>Strong recommendation</th>
<th>Low-quality evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendation may change when higher quality evidence becomes available.</td>
<td>Other alternatives may be equally reasonable.</td>
</tr>
</tbody>
</table>

References


How to Use This Pocket Guide

ASH pocket guides are primarily intended to help clinicians make decisions about diagnostic and treatment alternatives. These guidelines are not intended to serve or be construed as a standard of care. Clinicians must make decisions on the basis of the unique clinical presentation of an individual patient, ideally through a shared process that considers the patient’s values and preferences with respect to all options and their possible outcomes. Decisions may be constrained by realities of a specific clinical setting, including but not limited to institutional policies, time limitations, or unavailability of treatments. ASH pocket guides may not include all appropriate methods of care for the clinical scenarios described. As science advances and new evidence becomes available, these pocket guides may become obsolete. Following these guidelines cannot guarantee successful outcomes. ASH does not warrant or guarantee any products described in these guidelines.

Dr. Weinstein declares no competing financial interests.

To order this and other pocket guides, go to www.hematology.org/Store. © 2016 The American Society of Hematology

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or mechanical, including photocopy, without prior written consent of the American Society of Hematology.

For expert consultation on red blood cell transfusion and other hematologic diseases, submit a request to the ASH Consult a Colleague program at www.hematology.org/Consult (ASH members only).